Cite
APA Citation
Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Pocock, C., Smith, G., Byrne, J. L., de Lavallade, H., O'Brien, S. G., Coffey, T., Foroni, L., & Copland, M. (2017). de-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet, 4(7), e310–e316. http://access.bl.uk/ark:/81055/vdc_100047097750.0x000001